Pharma Marketing Blog represents the opinions of
John Mack
Publisher of
Pharma Marketing News.
We accept advertising relevant to the interests of our members.
For more information, see:
Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com
| Also see Pharma Marketing News OpEd Pieces |
WLF Watches FDA Watching Drug Ads
Posted: June 28, 2005The Washington Legal Foundation (WLF), a conservative watchdog group funded by businesses (including drug companies), last week launched the "FDA/DDMAC Watch" program to "scrutinize" FDA advertising regulations.DDMAC Watch's first action challenged an FDA warning letter regarding a TV ad for Eli Lilly & Co.'s adult ADD therapy, Strattera
What's really interesting, however, are the ties that bind WLF, FDA, and the Pharma industry.
What About Those Warning Letters? The WLF criticism of the Strattera warning letter comes at a time when the FDA is sharply increasing the number of warning letters sent to pharmaceutical companies.
There is at least one point made by the WLF that I can agree with.